Table 2. Association of BRMS1 promoter methylation in NSCLC tissues (n=57) and cfDNA (n=48) with patients' clinico-pathological features.
| |
BRMS1
promoter methylation |
|||||
|---|---|---|---|---|---|---|
|
Patients |
n |
|
|
n |
|
|
| Clinico-pathological feature | 57 | Tissues (%) | Pa | 44 | cfDNA | Pa |
| Tumour size (cm) |
|
|
0.594 |
|
|
0.500 |
| T1 (⩽3 cm) | 13 | 8 (61.5) | 11 | 6 (54.5) | ||
| T2 (>3 cm) | 35 | 22 (62.9) | 31 | 15 (48.3) | ||
| Unknown |
9 |
|
|
2 |
|
|
| Lymph node |
|
|
0.549 |
|
|
0.448 |
| Positive | 21 | 13 (61.9) | 19 | 10 (52.6) | ||
| Negative | 28 | 18 (64.3) | 24 | 11 (45.8) | ||
| Unknown |
8 |
|
|
1 |
|
|
| Stage |
|
|
0.185 |
|
|
0.192 |
| IA, IB | 18 | 13 (72.2) | 14 | 5 (35.7) | ||
| IIA, IIB, IIIA, IIIB | 31 | 17 (54.8) | 29 | 16 (55.2) | ||
| Unknown |
8 |
|
|
1 |
|
|
| Histology |
|
|
0.361 |
|
|
0.421 |
| Adenocarcinoma | 23 | 15 (65.2) | 20 | 13 (65.0) | ||
| Squamous cell carcinoma | 25 | 14 (56.0) | 23 | 11 (47.8) | ||
| Unknown |
9 |
|
|
1 |
|
|
| Sex |
|
|
0.580 |
|
|
0.640 |
| Male | 41 | 25 (61.0) | 34 | 17 (50.0) | ||
| Female | 11 | 7 (63.6) | 10 | 5 (50.0) | ||
| Unknown | 5 | |||||
Abbreviations: BRMS1=breast-cancer metastasis suppressor 1; cfDNA=cell-free DNA; NSCLC=non-small cell lung cancer.
a
χ2 analysis.